Show simple item record

dc.contributor.authorGorog, Diana
dc.contributor.authorLip, Gregory Y H
dc.date.accessioned2019-11-08T01:20:15Z
dc.date.available2019-11-08T01:20:15Z
dc.date.issued2019-09-10
dc.identifier.citationGorog , D & Lip , G Y H 2019 , ' Impaired Spontaneous/Endogenous Fibrinolytic Status as New Cardiovascular Risk Factor? JACC Review Topic of the Week ' , Journal of the American College of Cardiology , vol. 74 , no. 10 , pp. 1366-1375 . https://doi.org/10.1016/j.jacc.2019.07.030
dc.identifier.issn0735-1097
dc.identifier.otherPURE: 17107831
dc.identifier.otherPURE UUID: 2802db52-3dfd-4d0b-bbcd-a1e5e83a1615
dc.identifier.otherScopus: 85070966179
dc.identifier.urihttp://hdl.handle.net/2299/21867
dc.description© 2019 Published by Elsevier on behalf of the American College of Cardiology Foundation. All rights reserved.
dc.description.abstractEndogenous fibrinolysis is a powerful natural defense mechanism against lasting arterial thrombotic occlusion. Recent prospective studies have shown that impaired endogenous fibrinolysis (or hypofibrinolysis) can be detected in a significant number of patients with acute coronary syndrome (ACS) using global assays and is a strong marker of future cardiovascular risk. This novel risk biomarker is independent of traditional cardiovascular risk factors and unaffected by antiplatelet therapy. Most prospective prognostic data have been obtained using a global assay using native whole blood at high shear or plasma turbidimetric assays, which are described herein. Tests of endogenous fibrinolysis could be used to identify patients with ACS who, despite antiplatelet therapy, remain at high cardiovascular risk. This review discusses the impact of currently available medications and those in development that favorably modulate fibrinolytic status and may offer a potential new avenue to improve outcomes in ACS.en
dc.format.extent10
dc.language.isoeng
dc.relation.ispartofJournal of the American College of Cardiology
dc.subjectacute coronary syndrome
dc.subjectfibrinolysis
dc.subjectrisk factor
dc.subjectthrombolysis
dc.subjectthrombosis
dc.subjectCardiology and Cardiovascular Medicine
dc.titleImpaired Spontaneous/Endogenous Fibrinolytic Status as New Cardiovascular Risk Factor? : JACC Review Topic of the Weeken
dc.contributor.institutionDepartment of Clinical and Pharmaceutical Sciences
dc.contributor.institutionBasic and Clinical Science Unit
dc.contributor.institutionCentre for Health Services and Clinical Research
dc.contributor.institutionSchool of Life and Medical Sciences
dc.description.statusPeer reviewed
dc.date.embargoedUntil2020-09-02
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=85070966179&partnerID=8YFLogxK
rioxxterms.versionAM
rioxxterms.versionofrecordhttps://doi.org/10.1016/j.jacc.2019.07.030
rioxxterms.typeOther
herts.preservation.rarelyaccessedtrue


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record